Pfs Partners, LLC Abb Vie Inc. Transaction History

Pfs Partners, LLC

$177 Billion
Q3 2024

A detailed history of Pfs Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Pfs Partners, LLC holds 1,105 shares of ABBV stock, worth $195,651. This represents 0.12% of its overall portfolio holdings.

Number of Shares

1,105

Previous 1,220 9.43%

Holding current value

$195,651

Previous $209 Million 4.3%

% of portfolio

0.12%

Previous 0.13%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$163.84 - $199.33 $18,841 - $22,922	-115 Reduced 9.43%	1,105 $218 Million
Q2 2024 Jul 25, 2024	BUY	$154.79 - $180.76 $464 - $542	3 Added 0.25%	1,220 $209 Million
Q1 2024 Apr 15, 2024	BUY	$159.82 - $182.1 $16,461 - $18,756	103 Added 9.25%	1,217 $222 Million
Q4 2023 Jan 26, 2024	BUY	$137.6 - $154.97 $19,952 - $22,470	145 Added 14.96%	1,114 $173 Million
Q3 2023 Nov 30, 2023	BUY	$133.59 - $154.65 $534 - $618	4 Added 0.41%	969 $144 Million
Q2 2023 Nov 30, 2023	BUY	$132.51 - $164.9 $33,525 - $41,719	253 Added 35.53%	965 $130 Million
Q1 2023 Nov 30, 2023	SELL	$144.61 - $166.54 $4,049 - $4,663	-28 Reduced 3.78%	712 $113 Million
Q4 2022 Nov 30, 2023	BUY	$138.31 - $165.87 $276 - $331	2 Added 0.27%	740 $120 Million
Q3 2022 Nov 30, 2023	BUY	$134.21 - $153.93 $268 - $307	2 Added 0.27%	738 $99.1 Million
Q2 2022 Nov 30, 2023	SELL	$137.62 - $174.96 $1,926 - $2,449	-14 Reduced 1.87%	736 $113 Million
Q1 2022 Nov 30, 2023	SELL	$131.98 - $163.75 $4,619 - $5,731	-35 Reduced 4.46%	750 $122 Million
Q4 2021 Nov 30, 2023	BUY	$107.43 - $135.93 $84,332 - $106,705	785 New	785 $106 Million

Others Institutions Holding ABBV

# of Institutions

3,849

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $313B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pfs Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pfs Partners, LLC with notifications on news.

Account